AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

NCT04617821 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Borderline Resectable Pancreatic Cancer
Locally Advanced Pancreatic Adenocarcinoma

Interventions

DRUG: Nab paclitaxel plus gemcitabine
DRUG: mFOLFIRINOX

Sponsor

Fudan University